Montanide Isa51
Pancreas Neoplasms
Tokyo UniversityPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 31/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Pancreas Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Endotag-1 MediGene | Phase 2 | B |
Dostarlimab Hopital Foch | Phase 2 | B |
VITAMIN D Hopital Foch | Phase 2 | CCC |
Same molecule, other indications
Montanide Isa51 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →